Statement: Clinical Trials, Safety, and COVID-19

As a non-profit organization focused on strengthening mental health services, MAPS is committed to protecting the safety of our study staff and clinical trial participants. 

We are taking active measures to minimize the risk of exposure to the COVID-19 virus and adhere to physical distancing. As a result of this initiative, all of our clinical trials enrolling healthy volunteer participants are temporarily postponed. For our clinical trials treating participants with PTSD, the risks and benefits of ongoing participation for the current participants and study staff are constantly being weighed and determined on a case-by-case basis. All visits that can be conducted remotely are being done using teleconferencing. At this time, about half of our study sites are continuing with in-person day-long experimental sessions with MDMA or placebo, although this number is likely to decrease if the risk of exposure and public health interventions continues to increase. New enrollment of participants is temporarily on hold, and focus is being shifted to clinical trial protocols which can be done entirely by online visits.

Self-Care Resources

Our mission to maximize mental health and public benefit is more important than ever before. Despite these trying times, we will continue to lead the way in offering high-quality psychedelic research and education.

With appreciation,